THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
Dr. George Adams, Chairman of the Board and CEO, Ventripoint DiagnosticsBridging this gap with its VMS+ software that can simplify and enhance the detection of congenital heart defects is Ventripoint Diagnostics. The firm’s ‘first-of-its-kind’ diagnostic software develops an accurate 3D model of a heart using 2D ultrasound scans. The software enables clinicians to obtain cardiac metrics on all heart chambers within minutes, even if the scans are of poor quality (i.e. dropout, lack of visibility of endocardial borders, etc.). VMS+ is powered by Ventripoint Diagnostics’ knowledge-based reconstruction (KBR) algorithm, which leverages a database of previously defined heart images and anatomical landmarks from standard 2D echo images to construct a complete 3D model with a precision equivalent to MRI.
“We can obtain accurate and trustworthy findings for the right ventricle and right atrium using our AI-driven KBR algorithm that achieves accuracy at a scale not seen before,” says Dr. George Adams, Chairman of the Board and CEO of Ventripoint Diagnostics.
The company is paving the way for the effective treatment of Tetralogy of Fallot (ToF), the most common cyanotic congenital cardiac condition detected in infants and young children. Treating the disease has been a persistent challenge in the healthcare sector for years because clinicians struggle to identify the optimal point to surgically fix the RV pulmonary valve. If the surgery is performed early, the patient will require a reoperation and runs out of opportunities to receive reconstructive procedures, but when intervened too late, the right ventricle becomes too enlarged and when the new pulmonary valve is put in, the patient’s right ventricle will not be able to recover properly. VMS+ simplifies the treatment of ToF by measuring RV volumes repeatedly for faster quantification of ventricular size, volume, and function, thereby enabling practitioners to track the progression of the pulmonary valve and perform a timely replacement.
Ventripoint Diagnostics also resolves the requirement of general anesthesia in pediatric cardiac scans. Cardiac MRI requires the patient to remain motionless, which is difficult to achieve in toddlers without sedation. VMS+ is a more childfriendly experience than an MRI as it does not require the patient to be still for long periods. A real-world scenario highlighting the company’s competency in enhancing patient experiences is that of a pediatric cardiologist that has been a long-time user of the system. He could quickly scan a two-year-old patient using VMS+ while improving the overall patient experience by making it easier for the child’s parents to be present during the scan.
We can obtain accurate and trustworthy findings for the right ventricle and right atrium using our AI-driven KBR algorithm that achieves accuracy at a scale not seen before
The third iteration of the software, VMS+ 3.0, is a vendor neutral diagnostic aid that seamlessly integrates into a clinic or hospital infrastructure and works with echo images generated by any ultrasound device. Ventripoint Diagnostics’ inventive approach offers patients a superior diagnostic alternative while giving medical professionals the equipment to conduct precise scans and transform patient care.
Company
Ventripoint Diagnostics
Management
Dr. George Adams, Chairman of the Board and CEO, Ventripoint Diagnostics
Description
Ventripoint Diagnostics is the only company in the world that is able to take 2D ultrasound scans of the heart and create reliable 3D renditions using its VMS+ software. The VMS+ fills a void in the ability to assess a heart quickly using conventional 2D alternatives.
Ventripoint Diagnostics News
Ventripoint and at the Mazankowski Heart Institute to Collaborate to Conduct a World-First Study of the Changes in Cardiac Function during Pregnancy
Dr. Lisa Hornberger, Principal Investigator of study stated “We are very grateful to Ventripoint for their support through equipment of this exciting research endeavor. We know that women with heart disease, particularly congenital (from birth) heart disease have an increased risk of poor pregnancy outcomes. This Heart & Stroke Foundation of Canada funded research will explore the contribution of inadequate heart function (use of Ventripoint) and vascular health and their interaction to adverse pregnancy outcomes. Use of the Ventripoint system will facilitate cardiac function investigations even in women with more challenging heart geometry. It is anticipated this innovative work will lead to improved strategies to optimize the cardiovascular health of these mothers leading to healthier pregnancies and infants.”
Dr. Jonathan Windram, Co-investigator stated “We are grateful to Ventripoint for their continued support. The Ventripoint system has been proven to assess ventricular volumes and systolic function in patients with a variety of cardiac conditions and we are excited to have the ability to use this technology within our study.”
Cardiovascular disease complicates 1-4% of pregnancies and is more common in women with hypertensive disorders, which is the leading cause of maternal death (Ramlakhan, K.P., Johnson, M.R. & Roos-Hesselink, J.W, 2020). One of the areas of focus for the study will be looking at the vascular and ventricular function in pregnant women with cardiovascular disease.
A combination of vascular measuring techniques and heart assessments will be used to understand ventricular and vascular interactions in mothers during pregnancy. A study of this nature has never been attempted before and will provide fundamental information on changes in cardiac function during pregnancy.
The VMS+3.0 will be used to perform heart assessments in this study and will allow for quick, accurate and repeat measurements in this groundbreaking study of women’s health. The VMS+3.0 is gaining more traction in being used to assess different heart conditions in specific population groups due to its ease of use and accessibility.
The study is being funded by the Canadian Institutes of Health Research (CIHR), which is Canada's federal funding agency for health research. CIHR funds approximately one billion dollars each year to support the discoveries and innovations that improve health and strengthen the healthcare system.